MedPath

Investigation of Anti-obesity Properties of Lactobacillus Sakei in Obese Human Subjects

Not Applicable
Completed
Conditions
Obesity
Interventions
Dietary Supplement: Lactobacillus sakei
Registration Number
NCT03248414
Lead Sponsor
Seoul National University Bundang Hospital
Brief Summary

In this study, we are going to investigate the efficacy of Lactobacillus Sakei on reduction of fat mass assessed by DEXA compared to plaebo.

Detailed Description

We are going to enroll subjects whose BMI is equal to higher than 25, and randomly assigned study material or placebo at 1:1 ratio. The treatment duration is 12 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
114
Inclusion Criteria
  • age 20-65 years
  • BMI equal to higher than 25 kg/m2
Exclusion Criteria
  • under anti-obesity medication
  • uncontrolled diabetes
  • uncontrolled hypertension
  • any medications can influence to body weight such as thiazolidinedione, GLP-1 analogue, SGLT2 inhibitor, diuretics
  • thyroid function test abnormality
  • malignancy within 5 years
  • immune compromised hosts or under immune suppressants
  • antibiotics or probiotics withing 2 weeks
  • any intervention to reduce body weight within 6 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlLactobacillus sakei2 packs per day
Lactobacillus sakeiLactobacillus sakei2 packs per day
Primary Outcome Measures
NameTimeMethod
Fat mass change in 12-week12 weeks

fat mass is measured by DEXA

Secondary Outcome Measures
NameTimeMethod
Changes in body weight12 weeks

body weight change

Changes in waist circumference12 weeks

Waist circumference change

Glucose metabolism12 weeks

Changes in beta-cell function

Trial Locations

Locations (1)

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Gyeonggi, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath